The White House is imposing price limits on a future monoclonal antibody drug to prevent Covid-19 under a contract with Regeneron, STATNews’ Rachel Cohrs reports. The deal, which is part of the Project NextGen initiative and marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, requires the list price for a future Covid-19 drug to be the same or lower in the U.S. as in other high-income countries.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron Announces Updates to Board of Directors
- Regeneron CFO Robert Landry to retire, Christopher Fenimore to succeed
- Regeneron Provides Update on Planned Chief Financial Officer Transition
- Celularity enters Research Collaboration Services Agreement with Regeneron
- Regeneron treatment of myasthenia gravis granted FDA orphan status